Geneseq Biosciences
@geneseq.bio
Geneseq Biosciences is an innovative biotechnology company based in Melbourne, Australia, focused on advancing cancer diagnostics through genomics. www.geneseq.com.au
Pinned
Geneseq Biosciences
@geneseq.bio
· Jul 16
Genomic profiling helps assess melanoma risk by analyzing microRNA expressions in lesions. Researchers create a scoring system for malignancy by identifying microRNA signatures, aiming to standardize diagnostics. #MelanomaAwareness #GenomicTesting #SkinHealth
Empowering Patients: The 5‑Question Melanoma Diagnostic Checklist
📋 Download the checklist here:
https://www.geneseq.com.au/about-melaseq/melanoma-misdiagnosis-risks-realities/
#MelanomaAwareness #SkinHealth #PatientEmpowerment #EarlyDetection #DiagnosticExcellence #Pathology
📋 Download the checklist here:
https://www.geneseq.com.au/about-melaseq/melanoma-misdiagnosis-risks-realities/
#MelanomaAwareness #SkinHealth #PatientEmpowerment #EarlyDetection #DiagnosticExcellence #Pathology
August 1, 2025 at 3:20 AM
Empowering Patients: The 5‑Question Melanoma Diagnostic Checklist
📋 Download the checklist here:
https://www.geneseq.com.au/about-melaseq/melanoma-misdiagnosis-risks-realities/
#MelanomaAwareness #SkinHealth #PatientEmpowerment #EarlyDetection #DiagnosticExcellence #Pathology
📋 Download the checklist here:
https://www.geneseq.com.au/about-melaseq/melanoma-misdiagnosis-risks-realities/
#MelanomaAwareness #SkinHealth #PatientEmpowerment #EarlyDetection #DiagnosticExcellence #Pathology
Kerri, 35, had a mole her GP dismissed, but it later itched and bled. Its removal showed melanoma. She urges trusting instincts and seeking second opinions, as GPs correctly diagnose melanomas just 29% of the time. #SkinCheck #MelanomaAwareness #TrustYourInstincts #EarlyDetectionMatters
July 21, 2025 at 10:47 PM
Kerri, 35, had a mole her GP dismissed, but it later itched and bled. Its removal showed melanoma. She urges trusting instincts and seeking second opinions, as GPs correctly diagnose melanomas just 29% of the time. #SkinCheck #MelanomaAwareness #TrustYourInstincts #EarlyDetectionMatters
🩺 One Biopsy, Three Opinions, One Decision. Dr. Julia Marks got opinions from benign to melanoma. She asked, "Another opinion?", "Sub-specialist?", "Genomic tools?" With expert advice, she chose conservative treatment and is healthy. ✅
July 21, 2025 at 2:39 AM
🩺 One Biopsy, Three Opinions, One Decision. Dr. Julia Marks got opinions from benign to melanoma. She asked, "Another opinion?", "Sub-specialist?", "Genomic tools?" With expert advice, she chose conservative treatment and is healthy. ✅
Genomic profiling helps assess melanoma risk by analyzing microRNA expressions in lesions. Researchers create a scoring system for malignancy by identifying microRNA signatures, aiming to standardize diagnostics. #MelanomaAwareness #GenomicTesting #SkinHealth
July 16, 2025 at 11:02 PM
Genomic profiling helps assess melanoma risk by analyzing microRNA expressions in lesions. Researchers create a scoring system for malignancy by identifying microRNA signatures, aiming to standardize diagnostics. #MelanomaAwareness #GenomicTesting #SkinHealth
MicroRNAs influence gene activity and their disruption in melanoma aids cancer growth. This forms a molecular fingerprint separating melanoma from benign moles. Tracking these changes can enable earlier, precise diagnoses. #MelanomaAwareness #GenomicTesting #SkinHealth #NextGenMedicine
July 14, 2025 at 11:06 PM
MicroRNAs influence gene activity and their disruption in melanoma aids cancer growth. This forms a molecular fingerprint separating melanoma from benign moles. Tracking these changes can enable earlier, precise diagnoses. #MelanomaAwareness #GenomicTesting #SkinHealth #NextGenMedicine
Genetic markers in moles unveil melanoma insights. Small molecules show severity; genomic tech detects RNA shifts, aiding early cancer detection. Result? Greater accuracy in diagnosis with 'molecular profiles.' #MelanomaAwareness #GenomicTesting #SkinHealth #NextGenMedicine
July 13, 2025 at 11:42 PM
Genetic markers in moles unveil melanoma insights. Small molecules show severity; genomic tech detects RNA shifts, aiding early cancer detection. Result? Greater accuracy in diagnosis with 'molecular profiles.' #MelanomaAwareness #GenomicTesting #SkinHealth #NextGenMedicine
Diagnosing moles is tricky; misdiagnoses can cause anxiety or wrong treatment. Learn why it's complex and discover new tools.
Empower your health!
#MelanomaAwareness #DiagnosisMatters #KnowYourSkin
Empower your health!
#MelanomaAwareness #DiagnosisMatters #KnowYourSkin
July 10, 2025 at 6:15 AM
Diagnosing moles is tricky; misdiagnoses can cause anxiety or wrong treatment. Learn why it's complex and discover new tools.
Empower your health!
#MelanomaAwareness #DiagnosisMatters #KnowYourSkin
Empower your health!
#MelanomaAwareness #DiagnosisMatters #KnowYourSkin
Melanoma diagnosis varies greatly, showing tech limits. A 2017 study had only 25% agreement on atypical moles and 43% for early melanomas. Consider second opinions and stay informed on diagnostic tools for "early" or borderline lesions.
#Dermatology #MelanomaDiagnosis #Pathology #PatientSafety
#Dermatology #MelanomaDiagnosis #Pathology #PatientSafety
July 9, 2025 at 2:11 AM
Melanoma diagnosis varies greatly, showing tech limits. A 2017 study had only 25% agreement on atypical moles and 43% for early melanomas. Consider second opinions and stay informed on diagnostic tools for "early" or borderline lesions.
#Dermatology #MelanomaDiagnosis #Pathology #PatientSafety
#Dermatology #MelanomaDiagnosis #Pathology #PatientSafety
Diagnosing moles is tricky. Early melanoma diagnoses often vary, risking misdiagnoses. This may cause false reassurances or unnecessary surgeries. Researchers aim to improve detection. #MelanomaAwareness #DiagnosisMatters #KnowYourSkin
July 8, 2025 at 8:51 AM
Diagnosing moles is tricky. Early melanoma diagnoses often vary, risking misdiagnoses. This may cause false reassurances or unnecessary surgeries. Researchers aim to improve detection. #MelanomaAwareness #DiagnosisMatters #KnowYourSkin
Diagnosing moles is complex! Many early melanomas are misdiagnosed, leading to errors in treatment. We urgently need better detection tools. Join us this month to explore advancements in melanoma diagnosis.
#MelanomaAwareness #DiagnosisMatters #KnowYourSkin
#MelanomaAwareness #DiagnosisMatters #KnowYourSkin
July 7, 2025 at 11:45 PM
Diagnosing moles is complex! Many early melanomas are misdiagnosed, leading to errors in treatment. We urgently need better detection tools. Join us this month to explore advancements in melanoma diagnosis.
#MelanomaAwareness #DiagnosisMatters #KnowYourSkin
#MelanomaAwareness #DiagnosisMatters #KnowYourSkin
The Medical Minute:
Spotify: tinyurl.com/2p...
Apple Podcasts: tinyurl.com/p9...
YouTube:
 / @themedicalminuteshow
youtu.be/MQ4BTFldiZA?...
Spotify: tinyurl.com/2p...
Apple Podcasts: tinyurl.com/p9...
YouTube:
 / @themedicalminuteshow
youtu.be/MQ4BTFldiZA?...
Melanoma Medicine of Tomorrow: What you need to know today - The Medical Minute 2025 Ep 5
YouTube video by The Medical Minute with Dr Anne & Dr Moz
youtu.be
March 17, 2025 at 4:19 AM
The Medical Minute:
Spotify: tinyurl.com/2p...
Apple Podcasts: tinyurl.com/p9...
YouTube:
 / @themedicalminuteshow
youtu.be/MQ4BTFldiZA?...
Spotify: tinyurl.com/2p...
Apple Podcasts: tinyurl.com/p9...
YouTube:
 / @themedicalminuteshow
youtu.be/MQ4BTFldiZA?...
Congratulations to Australian Clinical Labs on achieving NATA approval for Melaseq™ Liquid Biopsy 🎉🧬 This certification confirms Melaseq™ as the world’s first blood test designed to aid in detecting early-stage invasive melanoma!
www.linkedin.com/pulse/genese...
www.linkedin.com/pulse/genese...
Geneseq Biosciences announces that Melaseq™ Liquid Biopsy for Melanoma Detection has secured NATA approval
Melaseq™ becomes the world’s first blood test designed to aid in the detection of early-stage invasive melanoma approved for clinical use, marking a significant advancement in cancer diagnostics. Melb...
www.linkedin.com
February 20, 2025 at 1:54 AM
Congratulations to Australian Clinical Labs on achieving NATA approval for Melaseq™ Liquid Biopsy 🎉🧬 This certification confirms Melaseq™ as the world’s first blood test designed to aid in detecting early-stage invasive melanoma!
www.linkedin.com/pulse/genese...
www.linkedin.com/pulse/genese...
Melanoma insights: 2 studies show immune checkpoint inhibitors and statins reduce recurrence risk by ~35% (HR ~0.65). ICIs cost ~$250k/year, statins ~$1.5k. Melaseq may stratify patients genetically, tailoring treatment for better outcomes and smarter spending.
www.linkedin.com/pulse/advanc...
www.linkedin.com/pulse/advanc...
📢 Advancements in Melanoma Treatment: A Tale of Two Approaches & The Role of Biomarkers
🌟 Two new studies from Australian medical research collaborations are shining a light on melanoma treatments, and despite their differences, they share a striking similarity: both reported a similar h...
www.linkedin.com
January 2, 2025 at 3:22 AM
Melanoma insights: 2 studies show immune checkpoint inhibitors and statins reduce recurrence risk by ~35% (HR ~0.65). ICIs cost ~$250k/year, statins ~$1.5k. Melaseq may stratify patients genetically, tailoring treatment for better outcomes and smarter spending.
www.linkedin.com/pulse/advanc...
www.linkedin.com/pulse/advanc...
Great response from the media to our announcement this week. Melaseq is the first diagnostic test for melanoma that was entirely designed, validated and approved in Australia! 🇦🇺 ☀️ 🧪
December 7, 2024 at 2:06 AM
Great response from the media to our announcement this week. Melaseq is the first diagnostic test for melanoma that was entirely designed, validated and approved in Australia! 🇦🇺 ☀️ 🧪
Reposted by Geneseq Biosciences
Have made a melanoma starter pack for people interested in melanoma - let me know if you want to be added
go.bsky.app/CVcGfDd
go.bsky.app/CVcGfDd
November 15, 2024 at 7:18 AM
Have made a melanoma starter pack for people interested in melanoma - let me know if you want to be added
go.bsky.app/CVcGfDd
go.bsky.app/CVcGfDd
Reposted by Geneseq Biosciences
Please share my story. ❤️
When I was 35, I was diagnosed with stage IIIb melanoma. I had two small children. I was terrified I wouldn't make it to Christmas. I had surgery to remove a ton of lymph nodes in my groin. Next, I started immunotherapy (Yervoy) to try to save my life. The plan was... /1
When I was 35, I was diagnosed with stage IIIb melanoma. I had two small children. I was terrified I wouldn't make it to Christmas. I had surgery to remove a ton of lymph nodes in my groin. Next, I started immunotherapy (Yervoy) to try to save my life. The plan was... /1
November 15, 2024 at 2:43 AM
Please share my story. ❤️
When I was 35, I was diagnosed with stage IIIb melanoma. I had two small children. I was terrified I wouldn't make it to Christmas. I had surgery to remove a ton of lymph nodes in my groin. Next, I started immunotherapy (Yervoy) to try to save my life. The plan was... /1
When I was 35, I was diagnosed with stage IIIb melanoma. I had two small children. I was terrified I wouldn't make it to Christmas. I had surgery to remove a ton of lymph nodes in my groin. Next, I started immunotherapy (Yervoy) to try to save my life. The plan was... /1
Reposted by Geneseq Biosciences
What is melanoma, who does it affect and how can people avoid it?
What is melanoma, who does it affect and how can people avoid it?
For people aged 25 to 49 melanoma is the second most common form of cancer, but the risk can be reduced
Over the past two decades, cancer cases in the UK have been rising twice as fast for people under the age of 50 compared with older age groups: almost…
dlvr.it
November 16, 2024 at 7:24 AM
What is melanoma, who does it affect and how can people avoid it?
New tools are needed to improve cutaneous melanoma diagnosis and risk stratification. microRNA signatures were validated via next-generation sequencing. This technology allows for increased automation laboratory throughput.
bmcmedgenomics.biomedcentral.com/articles/10....
bmcmedgenomics.biomedcentral.com/articles/10....
RNA-seq validation of microRNA expression signatures for precision melanoma diagnosis and prognostic stratification - BMC Medical Genomics
Background New diagnostic tools are needed to improve the diagnosis and risk stratification of cutaneous melanoma. Disease-specific microRNA signatures have been previously described via NanoString pr...
bmcmedgenomics.biomedcentral.com
November 23, 2024 at 1:51 AM
New tools are needed to improve cutaneous melanoma diagnosis and risk stratification. microRNA signatures were validated via next-generation sequencing. This technology allows for increased automation laboratory throughput.
bmcmedgenomics.biomedcentral.com/articles/10....
bmcmedgenomics.biomedcentral.com/articles/10....
Noninvasive molecular biomarkers are needed to improve the early, accurate, and precise diagnosis of invasive cutaneous melanoma.
academic.oup.com/bjd/article/...
academic.oup.com/bjd/article/...
Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma
The fatality of melanoma depends on the ability of malignant cells to gain entry into the bodys circulatory systems, a process recently understood to be co
academic.oup.com
November 23, 2024 at 1:49 AM
Noninvasive molecular biomarkers are needed to improve the early, accurate, and precise diagnosis of invasive cutaneous melanoma.
academic.oup.com/bjd/article/...
academic.oup.com/bjd/article/...
Successful treatment of cutaneous melanoma requires early, accurate diagnosis of clinically suspicious melanocytic skin lesions. Multiple studies highlight the challenge of providing accurate dx assessments and the need for disease-specific biomarkers.
www.tandfonline.com/doi/full/10....
www.tandfonline.com/doi/full/10....
Translation of A Circulating Mirna Signature of Melanoma Into A Solid Tissue Assay to Improve Diagnostic Accuracy and Precision
Aim: Successful treatment of cutaneous melanoma depends on early and accurate diagnosis of clinically suspicious melanocytic skin lesions. Multiple international studies have described the challen...
www.tandfonline.com
November 23, 2024 at 1:46 AM
Successful treatment of cutaneous melanoma requires early, accurate diagnosis of clinically suspicious melanocytic skin lesions. Multiple studies highlight the challenge of providing accurate dx assessments and the need for disease-specific biomarkers.
www.tandfonline.com/doi/full/10....
www.tandfonline.com/doi/full/10....
Dx of melanocytic neoplasms is challenging and subjective, lacking specific circulating or tissue-based biomarkers. Recently, Mel38, a circulating microRNA profile of melanoma, was described. This study examines Mel38 expression and its impact in solid tissue.
journals.plos.org/plosone/arti...
journals.plos.org/plosone/arti...
Characterisation and validation of Mel38; A multi-tissue microRNA signature of cutaneous melanoma
Background Histopathologic examination of melanocytic neoplasms can be challenging and subjective, with no specific circulating or tissue-based biomarkers currently available. Recently, a circulating ...
journals.plos.org
November 23, 2024 at 1:44 AM
Dx of melanocytic neoplasms is challenging and subjective, lacking specific circulating or tissue-based biomarkers. Recently, Mel38, a circulating microRNA profile of melanoma, was described. This study examines Mel38 expression and its impact in solid tissue.
journals.plos.org/plosone/arti...
journals.plos.org/plosone/arti...
Effective melanoma management relies on early diagnosis. Stages III and IV have limited treatment options and only 50% and 10–25% 5-yr survival. Identifying biomarkers that predict high recurrence and progression risk allows early intervention and improved survival.
www.mdpi.com/2218-273X/8/...
www.mdpi.com/2218-273X/8/...
Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine
Effective management of melanoma depends heavily on early diagnosis. When detected in early non-metastatic stages, melanoma is almost 100% curable by surgical resection, however when detected in late ...
www.mdpi.com
November 23, 2024 at 1:40 AM
Effective melanoma management relies on early diagnosis. Stages III and IV have limited treatment options and only 50% and 10–25% 5-yr survival. Identifying biomarkers that predict high recurrence and progression risk allows early intervention and improved survival.
www.mdpi.com/2218-273X/8/...
www.mdpi.com/2218-273X/8/...
In Australia, skin cancer spending surpasses all other malignancies. However, melanoma’s mortality rate has risen steadily for the past 50 years. Diagnostic errors and the absence of complementary molecular biomarkers hinder progress.
www.nature.com/articles/bjc...
www.nature.com/articles/bjc...
Development and validation of a plasma-based melanoma biomarker suitable for clinical use - British Journal of Cancer
British Journal of Cancer - Development and validation of a plasma-based melanoma biomarker suitable for clinical use
www.nature.com
November 23, 2024 at 1:35 AM
In Australia, skin cancer spending surpasses all other malignancies. However, melanoma’s mortality rate has risen steadily for the past 50 years. Diagnostic errors and the absence of complementary molecular biomarkers hinder progress.
www.nature.com/articles/bjc...
www.nature.com/articles/bjc...